VXRT (Vaxart) Total Current Liabilities: $73.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VXRT Vaxart Inc VXRT
49 GF Score
Price $0.47
! 3 Warning Signs
View Full Analysis

What is Vaxart Total Current Liabilities?

Vaxart VXRT -3.66% 49 Total Current Liabilities is $73.1 Mil as of Jun. 2026. GuruFocus rates VXRT with a GF Score™ of 49/100. The stock has 3 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Vaxart's total current liabilities for the quarter that ended in Jun. 2026 was $73.1

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Vaxart Total Current Liabilities Related Terms

Vaxart Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vaxart's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart Total Current Liabilities Chart

Vaxart Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.78 17.92 13.72 90.88 86.75

Vaxart Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 117.88 169.30 86.75 76.84 73.11
VXRT
49GF Score
Vaxart Inc VXRT
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxart Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Vaxart's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=65.131+4.359
+Other Current Liabilities+Current Deferred Liabilities
=4.244+13.02
=86.8

Vaxart's Total Current Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=57.413+5.227
+Other Current Liabilities+Current Deferred Liabilities
=2.687+7.781
=73.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $73.1 Mil mean?
Vaxart (VXRT) has a Total Current Liabilities of $73.1 Mil as of Jun. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Vaxart and its competitors.
Is Vaxart's Total Current Liabilities too high?
Vaxart's current Total Current Liabilities is $73.1 Mil. Overall, Vaxart has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Total Current Liabilities compare to ENGN and NTHI?
Vaxart's Total Current Liabilities of $73.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Vaxart and its competitors. Vaxart's current Total Current Liabilities is $73.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (VXRT) has a current Total Current Liabilities of $73.1 Mil. The current Total Current Liabilities is $73.1 Mil. Vaxart's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Vaxart (VXRT), the current Total Current Liabilities is $73.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxart Business Description

Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc. is a clinical-stage biotechnology company based in the United States that develops oral recombinant vaccines delivered in tablet form rather than by injection. Its vaccines are built on a proprietary vector-adjuvant-antigen platform that uses a modified adenovirus vector to elicit immune responses in the gastrointestinal tract and systemically. The company's development pipeline targets infectious diseases including norovirus, seasonal influenza, respiratory syncytial virus (RSV), human papillomavirus (HPV), and coronaviruses, with norovirus and coronavirus programs among its most advanced. Vaxart also develops a proprietary oral vaccine adjuvant and has explored tablet vaccine formulations intended to be room-temperature stable and self-administered. The company operates in a single reporting segment, the discovery and development of oral recombinant vaccines, and conducts its activities primarily in the United States. As a clinical-stage business, it has no approved products and generates no product revenue, funding operations through equity offerings, grants, and collaboration agreements.
49GF Score

Get the complete analysis for VXRT

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price